The US Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax Covid-19 vaccine for use in people 12 and up. Doses could be available by the end of next week.

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

As of 11:21 AM EDT. Market Open. Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects ...

The FDA has authorized Novavax's new formula, adding to a repertoire of revamped COVID vaccines. Here's what to know about cost and more. Jessica Rendall Wellness Reporter Jessica is a writer on ...

US Clears Updated COVID Shots From Novavax, Adding a 3rd Fall Vaccine Option U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already ...

U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $23.00. Mayank Mamtani has given his Buy rating due to a ...

Novavax’s vaccine is based on protein technology, which takes longer to manufacture than mRNA vaccines like those made by Pfizer and BioNTech and Moderna. Protein-based vaccines work by getting ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...